IGF-1 LR3

Overview

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic analog of human insulin-like growth factor 1 (IGF-1), one of the most potent natural activators of the Akt/mTOR signaling pathway — the central cellular cascade governing cell growth, proliferation, and survival. The "LR3" designation describes two key modifications to the native IGF-1 molecule: an N-terminal extension of 13 amino acids ("Long") and a substitution of arginine for glutamic acid at position 3 of the native sequence ("R3").

These modifications were introduced during the development of IGF-1 for bioprocessing applications (cell culture media supplementation) and research. The critical functional consequence is a dramatically reduced affinity for IGF binding proteins (IGFBPs), the family of six proteins that normally sequester circulating IGF-1, limit its bioavailability, and regulate its tissue-level activity. By evading IGFBP binding, IGF-1 LR3 remains in an active, free state for a significantly longer duration than native IGF-1.

Native IGF-1 is a 70-amino-acid peptide produced primarily by the liver in response to growth hormone (GH) stimulation, though local tissue production occurs in virtually every organ. It mediates many of the anabolic and growth-promoting effects attributed to growth hormone. IGF-1 LR3, at 83 amino acids, retains the receptor-binding activity of native IGF-1 while substantially extending its functional half-life through IGFBP evasion.

IGF-1 LR3 is widely used in cell culture and bioprocessing as a media supplement. It has not been approved for clinical use in humans and remains a research compound.

Structure and Sequence

IGF-1 LR3 is an 83-amino-acid single-chain polypeptide:

• Structure: Native IGF-1 sequence (70 amino acids) with a 13-amino-acid N-terminal extension peptide (MFPAMPLSSL) and Glu3 to Arg3 substitution
• Molecular weight: Approximately 9,111 Da (compared to 7,649 Da for native IGF-1)
• Disulfide bonds: Three intramolecular disulfide bonds (same as native IGF-1), critical for maintaining the tertiary structure required for receptor binding
• Key modification sites:
  • N-terminal extension: 13 additional amino acids reduce IGFBP affinity
  • Arg3 substitution: Further reduces IGFBP-3 and IGFBP-5 binding by disrupting the IGFBP interaction surface

For comparison, native IGF-1 shares approximately 50% sequence homology with insulin and signals through the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase structurally related to the insulin receptor.

Mechanism of Action

IGF-1 Receptor Activation

IGF-1 LR3 binds to and activates the IGF-1 receptor (IGF-1R) with affinity comparable to native IGF-1. IGF-1R is a transmembrane receptor tyrosine kinase that, upon ligand binding, undergoes autophosphorylation and initiates two major intracellular signaling cascades:

PI3K/Akt/mTOR Pathway:

• Recruitment and activation of phosphatidylinositol 3-kinase (PI3K)
• Akt (protein kinase B) phosphorylation and activation
• mTOR complex 1 (mTORC1) activation, driving protein synthesis through S6K1 and 4E-BP1 phosphorylation
• Inhibition of FOXO transcription factors, reducing protein degradation and apoptotic gene expression
• Glycogen synthase kinase 3 (GSK-3) inhibition, promoting glycogen synthesis

Ras/MAPK/ERK Pathway:

• Activation of the Ras-Raf-MEK-ERK mitogen-activated protein kinase cascade
• Promotion of cell proliferation, differentiation, and survival
• Regulation of gene transcription programs involved in cell cycle progression

IGFBP Evasion

The defining pharmacological advantage of IGF-1 LR3 over native IGF-1 is its reduced IGFBP binding:

• Native IGF-1 is approximately 95-99% bound to IGFBPs in circulation, primarily IGFBP-3 in a ternary complex with the acid-labile subunit (ALS)
• IGF-1 LR3 has approximately 100-fold lower affinity for IGFBP-3 compared to native IGF-1
• This results in a much higher proportion of free (bioactive) peptide available for receptor engagement
• The practical consequence is approximately 2-3 times greater potency in cell-based bioassays compared to native IGF-1

Muscle-Specific Effects

In the context of skeletal muscle biology, IGF-1R activation drives:

• Myoblast proliferation — Expansion of muscle precursor cell populations
• Satellite cell activation — Recruitment of quiescent satellite cells into the cell cycle
• Protein synthesis — mTORC1-dependent increase in translation initiation and ribosomal biogenesis
• Anti-catabolic effects — Akt-mediated suppression of the ubiquitin-proteasome and autophagy-lysosome proteolytic pathways
• Myogenic differentiation — Promotion of myoblast fusion and myotube formation

Insulin Receptor Cross-Reactivity

IGF-1 LR3 retains low but measurable affinity for the insulin receptor, particularly the IR-A isoform. This cross-reactivity underlies the glucose-lowering potential of IGF-1 analogs and represents a safety-relevant pharmacological property.

Research Summary

Pharmacokinetics

• Half-life: Approximately 20-30 hours (compared to approximately 12-15 minutes for free native IGF-1 in circulation). This extended half-life is the direct consequence of reduced IGFBP sequestration
• Bioavailability: High following subcutaneous injection, with more predictable pharmacokinetics than native IGF-1 due to reduced IGFBP interactions
• Peak levels: Reached within 1-2 hours post-subcutaneous injection
• Distribution: Distributed systemically; unlike native IGF-1, remains primarily in free form rather than bound in ternary complexes
• Metabolism: Degraded by tissue proteases; renal clearance of fragments
• IGFBP interaction: Approximately 1% of native IGF-1's affinity for IGFBP-3; does not form the classical ternary complex (IGF-1/IGFBP-3/ALS)
• Insulin receptor cross-reactivity: Retains low but physiologically relevant IR affinity; hypoglycemia risk at higher doses

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

Reconstitution

Dosing Schedule

Syringe Measurements (U-100 insulin syringe)

Cycle Guidelines

• Cycle length: 8 weeks on, 4-8 weeks off (to prevent receptor desensitization)
• Route: Subcutaneous injection
• Timing: Morning or post-workout; administer with or shortly after meals to mitigate hypoglycemia risk
• Injection sites: Rotate between abdomen, thighs, and upper arms
• Note: Monitor blood glucose, especially during dose escalation

Common Discussion Topics

1. Muscle growth and body composition — IGF-1 LR3 is discussed for its direct anabolic effects through the IGF-1R/Akt/mTOR pathway, independent of growth hormone administration
2. Comparison with GH and native IGF-1 — Discussions frequently compare IGF-1 LR3 to growth hormone therapy and native IGF-1 (mecasermin/Increlex) in terms of mechanism, potency, and side effect profile
3. Hypoglycemia risk — Insulin receptor cross-reactivity and the potential for glucose-lowering effects are significant safety topics
4. Local vs. systemic effects — Debate regarding whether site-specific injection produces localized hypertrophy or primarily systemic effects
5. Relationship to MGF — Comparison with Mechano Growth Factor (MGF), another IGF-1 splice variant, with discussion of distinct but complementary roles in muscle biology
6. Cell proliferation concerns — IGF-1 signaling promotes cell proliferation broadly, raising theoretical questions about tissue-specific growth and long-term safety

Limitations of Current Research

1. No human clinical trials — IGF-1 LR3 specifically has not undergone clinical trials; human IGF-1 data comes from native IGF-1 (mecasermin) studies
2. Non-selective growth promotion — IGF-1R activation promotes proliferation in many cell types, not exclusively muscle
3. Hypoglycemia risk — Insulin receptor cross-reactivity represents a genuine safety concern
4. Regulatory status — Classified as a research chemical; included on WADA prohibited list as a growth factor

Related Compounds

• MGF (Mechano Growth Factor) — an IGF-1 splice variant specific to mechanical loading and muscle repair
• Follistatin — a myostatin inhibitor with complementary muscle-growth mechanisms
• Native IGF-1 (Mecasermin/Increlex) — FDA-approved recombinant human IGF-1 for severe IGF-1 deficiency
• Des(1-3) IGF-1 — a truncated IGF-1 variant lacking the first three N-terminal amino acids, also with reduced IGFBP affinity
• IGF-2 — a related insulin-like growth factor with distinct receptor preferences and developmental roles